Comprehensive medication guide to Gimoti including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0 with qualifying commercial insurance after prior authorization approval; $20 if PA is denied or insurance does not cover Gimoti. Medicare/Medicaid patients are not eligible for the manufacturer copay program but many plans do cover Gimoti — copay varies by plan.
Estimated Cash Pricing
~$2,499–$2,825 retail per 9.8 mL bottle (4-week supply); most eligible commercial insurance patients pay $0 or $20 through Evoke Pharma's savings program via ASPN Pharmacies. No generic is available as of 2026.
Medfinder Findability Score
45/100
Summarize with AI
On this page
Gimoti is the brand name for metoclopramide nasal spray, the only FDA-approved nasal spray formulation of metoclopramide. It is manufactured by Patheon (a Thermo Fisher division) for Evoke Pharma, Inc. and received FDA approval in 2020 (NDA 209388). The active ingredient, metoclopramide, has been used in the United States since 1979 in oral and injectable forms.
Gimoti is FDA-approved for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis — a condition caused by diabetic nerve damage that slows or disrupts stomach muscle contractions, leading to delayed gastric emptying. Symptoms include nausea, vomiting, early satiety, bloating, abdominal fullness, and heartburn.
Gimoti is a specialty medication exclusively dispensed through ASPN Pharmacies. No generic version is available as of 2026. Most patients with commercial insurance pay $0 or $20 through Evoke Pharma's savings program. Gimoti is not a controlled substance.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Gimoti contains metoclopramide, a dopamine-2 (D2) receptor antagonist. In the GI tract, dopamine acts as a brake on stomach muscle contractions. By blocking D2 receptors, metoclopramide releases this inhibitory effect, which accelerates gastric emptying and enhances coordinated contractions in the upper GI tract.
Metoclopramide also blocks D2 receptors in the brain's chemoreceptor trigger zone (CTZ), which reduces nausea and vomiting. Additionally, it increases the resting tone of the lower esophageal sphincter, which helps reduce reflux symptoms commonly seen in gastroparesis.
The nasal route is clinically important in gastroparesis: because the stomach empties slowly, oral medications may also be absorbed erratically. Gimoti's nasal delivery bypasses the stomach entirely, providing more predictable pharmacokinetics. Gimoti 15 mg nasal spray is bioequivalent to oral metoclopramide 10 mg tablet.
15 mg/actuation — nasal spray
1 spray in 1 nostril, 30 minutes before each meal and at bedtime (up to 4x daily) for 2-8 weeks
Gimoti is not on the FDA drug shortage list as of 2026. However, finding it at a pharmacy is more complex than most medications because it is exclusively dispensed through ASPN Pharmacies — a specialty pharmacy. No retail chains (CVS, Walgreens, Rite Aid, etc.) carry Gimoti. Most patients also face a prior authorization requirement from their insurance that adds 7–30 business days to the process.
The findability score of 45 reflects these logistics-based access challenges rather than a manufacturing shortage. Patients who know to route their prescription to ASPN and enroll in the savings program can typically access Gimoti within 1–2 weeks.
For help navigating prescription access challenges across all your medications, medfinder contacts pharmacies on your behalf to confirm which ones can fill your prescriptions.
Gimoti is not a controlled substance and does not require a DEA special registration. Any licensed healthcare provider with prescribing authority in their state can write a Gimoti prescription. The prescription must be routed to ASPN Pharmacies — not a retail pharmacy.
Gastroenterologists — most experienced with diabetic gastroparesis diagnosis and management
Endocrinologists and diabetologists — frequently the first to identify gastroparesis as a diabetes complication
Primary care physicians (PCPs) and internal medicine physicians
Nurse practitioners (NPs) and physician assistants (PAs) — in states that allow prescribing authority
Telehealth providers experienced with gastroparesis can also prescribe Gimoti. Evoke Pharma's patient website (gimotirx.com) includes a telehealth connection feature. Note that confirming a gastroparesis diagnosis typically requires an in-person 4-hour gastric emptying study at an imaging center.
No. Gimoti (metoclopramide nasal spray) is not a DEA-controlled substance. It is not scheduled under the Controlled Substances Act and does not require any special DEA registration for prescribers to prescribe or pharmacies to dispense. Any licensed provider with prescribing authority in your state can write a Gimoti prescription.
However, Gimoti does carry a Black Box Warning — the FDA's most serious safety label — for tardive dyskinesia (TD), a potentially irreversible movement disorder. This warning is not related to controlled substance scheduling but to the risk associated with long-term dopamine D2 receptor blockade. Treatment with all metoclopramide products should not exceed 12 cumulative weeks.
The most common side effects of Gimoti nasal spray (≥5% in clinical trials) include:
Dysgeusia (altered or metallic taste) — the most unique nasal-route-specific side effect, reported in ~15% of patients
Headache
Drowsiness and fatigue
Restlessness (akathisia)
Lassitude (general weakness or lack of energy)
Tardive dyskinesia (TD) — potentially permanent involuntary movements; Black Box Warning
Extrapyramidal symptoms (EPS) — dystonia, parkinsonian symptoms, motor restlessness
Neuroleptic Malignant Syndrome (NMS) — rare but potentially fatal; high fever, rigid muscles, altered mental status
Methemoglobinemia — rare; higher risk in G6PD deficiency patients
Hyperprolactinemia — hormonal side effects including galactorrhea, amenorrhea, gynecomastia
Know what you need? Skip the search.
Oral Metoclopramide (Reglan)
Same active ingredient as Gimoti in tablet form. Generic available for $4–$20/month. Requires oral absorption, which can be erratic in gastroparesis. FDA-approved for the same indication.
Erythromycin
Macrolide antibiotic used off-label as a motilin receptor agonist to accelerate gastric emptying. Effective at low doses (40–150 mg before meals). Effects may diminish after ~4 weeks. AGA conditionally recommended.
Domperidone
Dopamine antagonist with fewer CNS side effects than metoclopramide. Not FDA-approved; available only via FDA Expanded Access IND program. Requires cardiac monitoring for QTc prolongation.
Ondansetron (Zofran)
Serotonin 5-HT3 antagonist antiemetic. Does not accelerate gastric emptying but reduces nausea and vomiting symptoms. Available generically. Often used alongside prokinetics.
Prefer Gimoti? We can find it.
Antipsychotics (haloperidol, risperidone, olanzapine, etc.)
majorAdditive dopamine D2 receptor blockade significantly increases tardive dyskinesia and extrapyramidal symptom risk. Avoid concurrent use.
Strong CYP2D6 inhibitors (fluoxetine, paroxetine, abiraterone, bupropion)
majorIncrease metoclopramide blood levels by inhibiting its metabolism. Gimoti dose cannot be adjusted. Not recommended.
CNS depressants (benzodiazepines, opioids, alcohol)
moderateAdditive CNS depression increases sedation and cognitive impairment. Avoid alcohol entirely during treatment.
Dopaminergic agents (amantadine, levodopa)
majorOpposing pharmacologic effects — metoclopramide blocks dopamine while these drugs enhance it. Can reduce effectiveness or worsen Parkinson's symptoms.
Digoxin
moderateMetoclopramide accelerates gastric emptying, potentially reducing digoxin absorption. Monitor digoxin levels.
Cyclosporine
moderateAccelerated gastric emptying may increase cyclosporine absorption. Monitor levels and renal function.
Gimoti represents an important innovation in the treatment of diabetic gastroparesis — the only FDA-approved nasal spray formulation of metoclopramide, offering a route of delivery that bypasses the very problem (delayed gastric emptying) that makes oral medications less effective in this population. For patients with severe nausea, vomiting, or swallowing difficulties, Gimoti provides a clinically meaningful alternative to oral tablets.
Access challenges are real but solvable: the key is knowing that Gimoti must go through ASPN Pharmacies, and that Evoke Pharma's savings program can reduce the cost to $0 or $20 for most commercially insured patients. Most patients who understand the system can begin treatment within 1–2 weeks of their prescription being written.
Whether you need Gimoti or another medication in your treatment regimen, medfinder helps you find which pharmacies can fill your prescriptions — quickly and without the phone calls.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini